Literature DB >> 61929

Experiences with the hematoxylin basic fuchsin picric acid staining method for morphologic diagnosis of myocardial ischemia - an experimental study in forensic pathology.

J Rajs, S Jakobsson.   

Abstract

An investigation was performed on 148 medicolegal autopsy cases with the purpose of obtaining experience with the hematoxylin basic fuchsin acid staining method for morphologic diagnosis of early myocardial ischemia. A comparative study was performed on rats with induced myocardial infarcts. The uptake of the basic fuchsin stain in myocardial sections agreed well with eosinophilia, often occurred when myocardial infarction was suspected, but very often yielded false positive and negative results. This lack of reliability probably depended on the high sensitivity of the staining procedure, degree of autolysis, fixation time, thickness of the sections and mainpulative lesions. Although the HBFP-technique does not seem sufficiently reliable in medicolegal autopsy cases it probably produces accurate results under controlled experimental conditions.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 61929     DOI: 10.1016/0300-9432(76)90045-5

Source DB:  PubMed          Journal:  Forensic Sci        ISSN: 0300-9432


  4 in total

1.  Susceptibility of C5b-9(m) to postmortem changes.

Authors:  H Thomsen; H Held
Journal:  Int J Legal Med       Date:  1994       Impact factor: 2.686

2.  Demonstration of myocardial infarction in putrefying bodies.

Authors:  G G Fechner; S Sivaloganathan
Journal:  J Clin Pathol       Date:  1987-08       Impact factor: 3.411

3.  [Early recognition of hypoxic lesions in the cerebellum using Lie staining (HBFP staining)].

Authors:  O Pribilla; M Tönnies
Journal:  Z Rechtsmed       Date:  1983

4.  Exercise preconditioning initiates late cardioprotection against isoproterenol-induced myocardial injury in rats independent of protein kinase C.

Authors:  Yu-Jun Shen; Shan-Shan Pan; Tao Zhuang; Feng-Juan Wang
Journal:  J Physiol Sci       Date:  2010-10-13       Impact factor: 2.781

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.